Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06463743 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 15, 2025 to Sep 24, 2025
    v8
  2. Start date: Aug 1, 2025 to Oct 15, 2025v7
  3. Primary completion date: Apr 2026 to Jan 1, 2027
    • Study completion date: Oct 2026 to Jun 1, 2027
    v6
  4. Start date: May 15, 2025 to Aug 1, 2025v5
  5. Start date: Apr 1, 2025 to May 15, 2025v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Jan 2025 to Apr 1, 2025v3
  2. Start date: Aug 2024 to Jan 2025
    • Primary completion date: Nov 2025 to Apr 2026
    • Study completion date: May 2026 to Oct 2026
    • Collaborators expanded, about 7 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of the study is to learn about treating older people with multiple sclerosis (MS) with metformin. Metformin may be used as a single therapy or as an add-on therapy. The investigators want to learn: * The safety and tolerability of metformin extended release (1500 mg/day) as a single therapy or as an add-on therapy in older people with MS compared to placebo * How well metformin protects the nervous system against injury compared with placebo measured by brain MRI over a 9 month treatment period * The effect of metformin to protect brain tissue from age and MS related injury when compared to the placebo group over a 9 month treatment period
Trial Details
NCT Number NCT06463743
Lead Sponsor State University of New York at Buffalo
Collaborators: National Center for Advancing Translational Sciences (NCATS)
Conditions
(from sponsor)		 Multiple Sclerosis
Related terms Multiple Sclerosis
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov